Bluewater Bio’s growth continues with board appointment of industry expert Dr Piers Clark

Posted: Wednesday 12th May 2010

Bluewater Bio Limited, a global specialist in the treatment of wastewater, is delighted to announce the appointment as Non-executive Director of Dr Piers Clark, a renowned technical and industry expert within the water and energy sectors. This board appointment comes at a time when Bluewater Bio is hitting significant milestones in the global roll-out of its HYBACS (Hybrid Bacillus Activated Sludge) technology, driven by increased legislative and economic demand for water management and re-use.

Dr Clark brings to Bluewater Bio over 20 years’ experience in the water, waste and utilities industries, since joining North West Water as a Research Scientist in 1994. His most recent position has been as Interim Asset Director with Thames Water, one of the UK's largest water and wastewater services companies. Prior to this, Dr Clark served as Managing Director for Utilities at Mouchel Ltd and Management Board Member of parent Group Mouchel plc, the global engineering consultancy firm with 11,000 employees, focused especially on the UK, Ireland and the Gulf States. During his five years at Mouchel, where he led a team of around 3000 staff across the water, energy, environment and rail sectors, Dr Clark saw turnover treble and profits increase nearly six-fold. Primary achievements include the coordination of key international acquisitions and driving innovation across the utilities sector through his leading role in the Mouchel-sponsored industry-wide Technology Approvals Group (TAG).

Dr Clark currently holds a Non-executive Director position at Empire Water in California and is also active within the sector’s financial community, where he advises the Emerald Cleantech fund. In the UK, he currently serves as a member of the industry regulator OFWAT’s Future Regulation Advisory Panel. Additionally, Dr Clark, a PhD in Civil and Environmental Engineering, has published over 30 technical papers and several patent applications.

Commenting on his appointment, Dr Clark said: “I am delighted to have joined the Board of Bluewater Bio. This company has tremendous potential to improve wastewater treatment worldwide with its highly successful HYBACS technology. As a Non-executive Director, I believe that my experience in the sector can readily be leveraged by the team at Bluewater Bio throughout this exciting stage in their development and beyond. With the high performance shown by its two independent pilot trials with utility partners Severn Trent Water in the UK and Aqualia in Spain, and its strategic partnerships in the Middle East, Africa and Europe, Bluewater Bio is in an excellent position to experience accelerated industry uptake of its HYBACS technology across the globe.”

Adrian Harris, Chief Operating Officer of Bluewater Bio, said: “We have enjoyed highly productive informal discussions with Dr Clark over several months, and are now delighted to be able to harness his industry knowledge and experience with a formal appointment to our team as a Non-executive Director. Bluewater Bio is strategically interested in the potential acquisition of synergistic technology companies in our wider field, and Dr Clark has an unparalleled exposure to and knowledge of these upcoming technologies through his leading role in the Mouchel-sponsored Technology Assessment Group (TAG).”

Read the magazine online

December 2019

About the magazine »
Magazine archive »


Information for advertisers »

Huber Prominent Fluid Controls Verder Xylem Pulsar Button June 13 Harvey Communications British Water Water Aid buttonwood marketing wateractive